Citations

Clear

4610 citation(s) found for "Lu, Brian".

Exploring a weighted composite score for harmonization of 18F‐MK6240 and 18F‐ Flortaucipir: linearity and correlations with cognitive measures in a head‐to‐head tau PET dataset – The HEAD Study
Finn, Quentin, Franco, Andrea , Vo, Tam , Amaral, Lívia , Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Baker, Suzanne L. , Masdeu, Joseph C. , Povala, Guilherme , Bauer‐Negrini, Guilherme , Franco, Andrea, Vo, Tam, Lussier, Firoza Zubeida , Gordon, Brian A. , Klunk, William E. , Rosa-Neto, Pedro , Masdeu, Joseph C , Pascoal, Tharick Ali , Pascual, Belén

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089551 Get It

AbstractBackgroundHarmonization of the two most commonly used Tau PET tracers, 18F‐Flortaucipir and 18F‐MK6240 has proven to be complex. Unlike the centiloid scale for amyloid tracers, Tau PET SUVRs of the two tracers are not linearly comparable and vary markedly in dynamic range and sensitivity.MethodTau PET SUVRs for Braak stage (1‐6) in 18F‐MK6240 and 18F‐Flortaucipir were obtained from the Longitudinal multicenter head‐to‐head harmonization of tau‐PET tracers (HEAD) project. For training, we used 13 amyloid confirmed AD, 24 amyloid confirmed MCI and 66 amyloid negative controls. To assess linearity and correlations with neuropsychological tests, we included the training data as well as 74 subjects of unknown or inconsistent amyloid status. Two methods of generating outcome measures were used. (1) As a stand‐in for Tau load, similar to the centiloid scale, a score of 100, 50 or 0 was given to participants of the training set by multiplying CDR score by 100. Hierarchical and ridge regression were performed for each tracer using PET‐Braak SUVRs as predictive variables. Regression coefficients were used to calculate an outcome measure for all participants. (2) Principal component analysis (PCA) was applied for each tracer to the vectors of PET‐Braak regional SUVR of the training subset. Projections along the principal axis were calculated for both modalitiesResultHierarchical, ridge regression and PCA all yielded composite measures with good linear dependence between the two tracers (r2 for hierarchical, ridge and PCA were 0.84, 0.80, 0.80, respectively). Regions remaining in the hierarchical regression analyses varied between tracers: predictive regions for 18F‐MK6240 were PET‐Braak 1, 4 and 5, while 18F‐Flortaucipir used only PET‐Braak 1 and 5. Composite measures correlated well with MMSE and total MOCA score with all composite measures r < ‐0.61.ConclusionWhile both tracers may have different sensitivities to regional Tau distributions and disease stages, weighting multiple regions differently for each tracer gives a composite score linearly comparable across tracers that correlates with neuropsychological measures. This study is limited by the low total tau load and impairment level of all participants and would benefit from the inclusion of patients with more disease progression.
Brain Volumetric Trajectories in Down Syndrome and Autosomal Dominant Alzheimer Disease
Kennedy, James Tyler, Boerwinkle, Anna H. , Price, Julie C. , Sathishkumar, Mithra , McMillan, Liv , Laymon, Charles M. , Krinsky‐McHale, Sharon J. , Lai, Florence , Rosas, H. Diana , Lott, Ira T. , Chhatwal, Jasmeer P. , Chui, Helena C., Farlow, Martin R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Schupf, Nicole , Mapstone, Mark , Christian, Bradley T. , Wisch, Julie K. , Gordon, Brian A. , Benzinger, Tammie L.S. , Klunk, William E. , Rafii, Michael S. , O’Bryant, Sid E. , Yassa, Michael A. , Brickman, Adam M. , Lao, Patrick , Hartley, Sigan L. , Zaman, Shahid H. , Lee, Joseph H. , Allegri, Ricardo , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Day, Gregory S. , Lee, Jae‐Hong , Xiong, Chengjie , Martins, Ralph N. , Sánchez‐Valle, Raquel , Schofield, Peter William , Hassenstab, Jason , McDade, Eric , Bateman, Randall J. , Handen, Benjamin L. , Head, Elizabeth , Ances, Beau M.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089313 Get It

AbstractBackgroundAlzheimer disease (AD) related cognitive decline occurs at relatively young ages in individuals with Down syndrome (DS, early‐mid 50s) and in those with autosomal dominant mutations (ADAD, 40‐50s). Both groups show similar patterns of amyloid accumulation. We examined if brain volumes are similarly affected by AD pathology in individuals with DS and ADAD.MethodData for cognitively stable and declining participants was obtained from the Alzheimer Biomarker Consortium‐Down Syndrome (ABC‐DS) and the Dominantly Inherited Alzheimer Network (DIAN). Stability/decline was identified based on cognitive testing and interview of individuals and caregivers by trained assessors. Cognitively stable family members without DS/ADAD mutations were recruited as controls from both studies. Participants underwent MRI and amyloid positron emission tomography (PET) scans from which brain volumes and amyloid (centiloids) were derived, respectively. Participants from DIAN had Pittsburgh Compound‐B (PIB) scans, ABC‐DS had PIB or florbetapir. Nonlinear cross‐sectional associations between regional brain volumes and estimated years to onset of cognitive decline (EYO, negative values before onset, positive after) and centiloid were evaluated using generalized additive models while controlling for sex and random effects of family. EYO was set to 52 for all participants with DS and based on parental decline/mutation type for participants with ADAD. EYO for controls was based on the EYO of their family member.ResultData from 239 participants with DS (47 declining), and 340 participants with ADAD (122 declining), and 263 familial controls were included. Higher EYO and centiloid values were associated with lower brain volumes in almost all regions. At earlier EYOs, individuals with DS typically had smaller regional volumes than ADAD or sibling controls, with volume declining linearly across the EYO range. By contrast, ADAD mutation carriers had similar volumes to non‐carriers at early EYOs, with volumes diverging as early as 10 years before decline. Brain volumes and centiloid values were inversely related in ADAD and DSAD. Volume in key cortical regions were similar by the expected year of onset in both groups.ConclusionADAD and DSAD demonstrated different temporal patterns of regional neurodegeneration prior to cognitive change despite being similarly affected by early onset amyloid.
Voxel‐wise comparison of [18F]MK6240 and [18F]Flortaucipir for the diagnosis of individuals across the Alzheimer’s disease spectrum – the HEAD study
Amaral, Lívia , Lowe, Val J. , Soleimani‐Meigooni, David N. , Oh, Hwamee , Tudorascu, Dana , Jagust, William J. , Baker, Suzanne L. , Bellaver, Bruna , Povala, Guilherme , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Ferreira, Pâmela C.L. , Klunk, William E. , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092862 Get It

AbstractBackgroundIn vivo studies using the tau PET tracers have shown high performance for the diagnosis of Alzheimer’s disease dementia and patterns of tracer uptake that resemble those observed in post‐mortem studies. However, tau tracers present distinct patterns of binding that might influence their performance in detecting AD pathology. In a head‐to‐head study, we investigated the performance of [18F]MK6240 and [18F]Flortaucipir for the diagnosis of AD.MethodWe assessed 132 individuals from the HEAD study (58 CU Aβ‐, 15 CU Aβ+, 14 MCI Aβ‐, 32 MCI Aβ+ and 13 AD dementia) with Aβ‐PET, [18F]MK6240 and [18F]Flortaucipir. Voxel‐wise receiver operating characteristic curves (ROC) of the two tau tracers were used to contrast groups provided the area under the curve (AUC) for disease diagnosis or biomarkers positivity.ResultThe brain maps showed numerically higher and more spread AUC for [18F]Flortaucipir to discriminate CU Aβ‐ from CU Aβ+ (Figure 1A). The difference between tracers’ AUC was greater in Braaks IV and V (Figure 2A), both regions that are not expected to have tau accumulation in CU Aβ+ individuals, reflecting a potential off‐target binding for [18F]Flortaucipir. To differentiate CU Aβ‐ from MCI Aβ+ individuals, [18F]MK6240 presented a numerically higher AUC than [18F]Flortaucipir in Braak I and II and similar AUC in other Braak regions (Figure 1B, 2B). We observed a high performance of [18F]MK6240 and [18F]Flortaucipir in differentiating AD dementia from CU Aβ‐ individuals. However, [18F]MK6240 exhibits a higher AUC than [18F]Flortaucipir in all Braak regions, especially Braak V‐VI (Figure 1C, 2C). Finally, [18F]MK6240 presented higher AUC in all Braak regions to discriminate MCI Aβ‐ from MCI Aβ+ individuals (Figure 1D, 2D).ConclusionOur results indicate that [18F]MK6240 and [18F]Flortaucipir present high accuracy to discriminate AD from CU Aβ‐ individuals. However, [18F]MK6240 presents higher AUC to discriminate AD and MCI Aβ+ from CU Aβ‐ individuals than [18F]Flortaucipir. Together, our head‐to‐head study sheds light on the distinct patterns of binding for Tau‐PET tracers.
CU PET Aβ and Tau Positive Individuals Show Impairment in MoCA Delayed Recall
Felix, Cynthia, Kollasserry, Felix Joy, Snitz, Beth E. , Rebok, George W. , Tudorascu, Dana , Oliveira, Markley, Lemaire, Peter Charles , Abbas, Sarah , Amaral, Lívia , Lowe, Val J. , Oh, Hwamee , Soleimani‐Meigooni, David N. , Jagust, William J., Baker, Suzanne L. , Ferreira, Pâmela C.L. , Rodrigues, Matheus Scarpatto , Povala, Guilherme , Bauer‐Negrini, Guilherme , Medeiros, Marina Scop , Soares, Carolina , Aguzzoli, Cristiano Schaffer , Bellaver, Bruna , Lussier, Firoza Zubeida , Pascual, Belén , Gordon, Brian A. , Klunk, William E. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092683 Get It

AbstractBackgroundIdentification of cognitively unimpaired (CU) individuals who may progress to mild cognitive impairment (MCI), is a pressing issue in the Alzheimer’s disease (AD) field, since therapeutic interventions may be more effective in the absence of cognitive impairment and neurodegeneration. CU individuals positive for amyloid and tau PET are very likely in the AD pathway. In out‐patient cognitive screening, we use rapid and simple tests such as The Montreal Cognitive Assessment (MoCA) ‐ a composite of executive, visuospatial, naming, attention, language, abstraction, delayed recall, and orientation performances. We hypothesize that sub‐categorizing the CU group based on the presence of amyloid (A) and tau (T) pathologies, as measured by PET, can reveal subtle cognitive deficits, even in a clinical test with low sensitivity such as MoCA.MethodWe included 88 CU [defined as CDR global score of 0] older adults with available head‐to‐head MK6240 tau‐PET and Flortaucipir tracers from the ongoing HEAD multi‐site observational study. They also underwent Amyloid PET imaging using PiB or NAV4694. MoCA testing was done around the imaging time. To increase similarity with clinical practice, Amyloid and Tau PET positivity was defined using visual reads. Based on tracer uptake status, we categorized the individuals into A‐T‐, A‐T+, A+T‐ and A‐T‐ groups. Unpaired t‐test and one‐way ANOVA were used to test for significant differences between groups.Result2‐tailed p‐values were significant between the A‐T‐ group and the A+T+ group for MoCA total score [p: 0.0025 and p: 0.0025]. When we stratified MoCA in the different cognitive domains, we found that the results were driven by MoCA (memory) Delayed Recall score [p: 0.0007 and p: 0.0162]. A‐T+ vs A+T+ was also significant [p: 0.0099] for MoCA Delayed Recall. Both tau tracers (MK6240 and Flortaucipir) showed similar performance for determining T+ and identifying cognitive decline.ConclusionMoCA, a simple and commonly administered in‐office neuropsychological test, can detect subtle cognitive dysfunction in CU older adults who are Aβ and tau positive (A+/T+). These CU A+/T+ individuals are likely on the path to developing AD dementia.
International Initiative for Harmonization of Plasma Neurofilament light chain NfL clinical reporting in neurodegenerative diseases
Olsen, Dorte Aalund , Alcolea, Daniel, Bigot‐Corbel, Edith , Bjerke, Maria , Perez, Mercedes Carretero, Chabrashvili, Tinatin, Chapman, Miles, Fourier, Anthony , Kaczorowski, Flora, Köertvelyessy, Pèter, Blanc, M, Mroszko, Barbara, Nogueira, Léonor, Garay, Raquel Perez, Quillard‐Muraine, Muriel, Borja, Enrique Rodriguez, Schraen, Susanna, Terracciano, Daniela , Tzartos, Socrates J., Unterwalder, Nadine, Yriarte, Jose, Blennow, Kaj , Delaby, Constance , Teunissen, Charlotte E. , Alcolea, Daniel , Lleó, Alberto , Algeciras‐Schimnich, Alicia , Santos, Gustavo Alves Andrade dos , Bouaziz-Amar, Élodie , Ayrignac, Xavier , Baldeiras, Inês , Perez, Mercedes Carretero, Casoli, Tiziana , Cusato, Jessica , Dursun, Erdinç , Galimberti, Daniela , Gezen‐Ak, Duygu , Gordon, Brian A. , Hart, Melanie , Herwerth, Marina , Kasuga, Kensaku , Keshavan, Ashvini , Khalil, Michael , Kühle, Jens , Ladang, Aurélie , Lewczuk, Piotr , Logroscino, Giancarlo , Tsolaki, Magda , Giuffrè, Guido Maria , Musso, Giulia , Kulczyńska‐Przybik, Agnieszka , Paquet, Claire , Parchi, Piero , Parnetti, Lucilla , Poesen, Koen , Quadrio, Isabelle , Tumani, Hayrettin , Vermunt, Lisa , Wellington, Cheryl L. , Zetterberg, Henrik , Lehmann, Sylvain

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.090643 Get It

AbstractBackgroundThe quantification of neurofilament light chain (NfL) in blood and cerebrospinal fluid (CSF) has proved useful in many contexts, for the diagnosis and prognosis of various neurological disorders. There is, however, a diversity of practices between centers, essentially linked to the context of use (COU), analytical methods, consideration of comorbidities, determination of cut‐points or use of interpretation scales. Finally, for the same biochemical profile, the interpretation and reporting of results may differ from one center to another, raising the question of test commutability. To date, no consensus has been reached between the different laboratories involved to define the most appropriate conclusions/comments based on COU and cut‐points. This work is an essential step towards consensual harmonization of the clinical use of NfL after CSF and/or blood analysis in various neurological contexts, as advocated by the Alzheimer's Association "Biofluid Based Biomarkers PIA" working group.MethodThis international project involves 58 clinical laboratories in 16 countries, specializing in the biochemical diagnosis of neurological disorders. By means of a questionnaire, we obtained a description of the COU, pre‐analytical and analytical (biological fluid and method used to quantify NfL) protocols of all the centers involved.ResultsOf the centers, 42% quantified NfL in CSF, 29% in serum and 28% in plasma, and 1% in dried blood spot. The COUs were as follows: Frontotemporal dementia (FTD, 17%), Alzheimer's disease (AD, 16%), multiple sclerosis (MS, 16%), amyotrophic lateral sclerosis (ALS, 11%), psychiatric syndrome (PS, 10%), Creutzfeldt‐Jakob disease (CJD, 8%), Parkinson's disease (PD, 8%), peripheral neuropathy (PN, 7%) and traumatic brain injury (TBI, 7%). Most centers define pathological cut‐points based on published literature and take age into account (50%).ConclusionOur initial results highlight the state of the art in terms of the clinical use of NfL analysis in CSF and blood in the context of different neurological diseases. We have now defined a coordinator for each COU subgroup and are organizing consensus meetings to harmonize the use and reporting of NfL measurements for the identified clinical applications. The results of these next steps will be presented.
Cerebrovascular reactivity (CVR) MRI as a biomarker for cerebral small vessel disease (SVD) related cognitive decline: Multi‐site validation in the MarkVCID Consortium
Hazel, Kaisha , Pottanat, George , Xu, Cuimei, Lucke, Emma, Gold, Brian T. , Greenberg, Steven M. , Helmer, Karl G. , Kramer, Joel H. , Mulavelil, Rachel, Singh, Herpreet , Velarde, Angel G., Kalyani, Rita R. , Rosenberg, Paul B. , Albert, Marilyn , Liu, Peiying , Lin, Zixuan , Jiang, Dengrong , Pillai, Jay J. , Bauer, Christopher E. , Jann, Kay , Jicha, Gregory A. , Maillard, Pauline , Satizábal, Claudia L. , Schwab, Kristin , Seshadri, Sudha , Wang, Danny J.J. , Moghekar, Abhay , Yaşar, Sevil , Lu, Hanzhang

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089224 Get It

AbstractBackgroundCerebral small vessel disease (SVD) related vascular contributions represent a major factor contributing to cognitive decline and dementia (VCID) in older adults. However, there has not been a validated biomarker for the diagnosis and treatment monitoring of this condition. Recently, the US National Institute on Neurological Disorders and Stroke (NINDS) funded the MarkVCID Consortium to identify and validate clinical‐trial‐ready biomarkers for VCID. Cerebrovascular reactivity (CVR) MRI is one of the selected biomarkers that underwent multi‐site testing in the Consortium. The present study aimed to report the relationship between CVR and cognitive function at independent sites, based on a pre‐specified hypothesis.MethodCVR, the ability of cerebral small vessels to dilate upon stimulus, is thought to directly reflect physiological function of the brain microvasculature. Based on previous single‐site findings, the pre‐defined hypothesis was that CVR will be associated with the global cognitive function measured by Montreal Cognitive Assessment (MoCA) after adjusting for age, sex, and education, and this association will be observed in data collected and analyzed at each individual site.A total of 264 older participants from three sites were included (Table 1). Each site performed an identical CVR MRI procedure using 5% CO2 inhalation, and a standardized clinical and cognitive evaluation. Multi‐linear regression analysis was conducted on a site‐by‐site basis to examine the pre‐defined hypothesis.ResultGray‐matter CVR showed a positive association with MoCA score after adjustment for age, sex, and education, in which participants with higher CVR had higher MoCA scores. This relationship was reproduced at each site (Figure 1, p<0.05 for each), confirming our pre‐specified hypothesis.In the secondary analysis of all data together, higher gray‐matter CVR was found to be significantly associated with better executive function measure of item response theory (IRT) score (β=2.87, p=0.003).ConclusionThe present study evaluated the relationship between CVR and cognition in a multi‐center setting. CVR was found to be positively associated with global cognitive function measured by the MoCA, which was shown to be reproducible across different sites with diverse cohorts. These findings support the utility of CVR as a biomarker in future clinical trials of SVD and VCID.
Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma
Kshirsagar, Rijul S. , Harris, Jacob , Chang, Eugene H. , Fung, Nicholas , Hong, Michelle , Johnson, Brian J. , Kohanski, Michael A. , Lee, Jivianne T. , Nabavizadeh, Seyed Ali , Obermeyer, Isaac P. , Pandrangi, Vivek C. , Smith, Timothy L. , Wang, Marilene B. , Lazor, Jillian W. , Mitchell, Tara C. , Adappa, Nithin D. , Adappa, Nithin D. , Harris, Jacob , Lee, Jivianne T , Obermeyer, Isaac P , Smith, Timothy L , Snyderman, Carl H , Kuan, Edward C , Kshirsagar, Rijul S , Eide, Jacob G. , Abiri, Arash , Beswick, Daniel M. , Fung, Nicholas, Le, Christopher H. , Pinheiro‐Neto, Carlos , Suh, Jeffrey D. , Wang, Eric W , Choby, Garret , Geltzeiler, Mathew , Adappa, Nithin D.

Mayo Clinic

American Journal of Rhinology & Allergy | January 9, 2025 | Volume: 39 | Issue: 2 | Pages: 102-108

10.1177/19458924241308953 | PMID 39782303 Get It

Background Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma. Objective We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma. Methods A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded. Results 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT ( n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab ( n = 17, 32.7%) or pembrolizumab ( n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively. Conclusion Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.
Universal tau PET scale (Uniτ) – The HEAD Study
Amaral, Lívia , Tudorascu, Dana , Lopresti, Brian J. , Jagust, William J. , Lowe, Val J. , Soleimani‐Meigooni, David N. , Oh, Hwamee , Povala, Guilherme , Bauer‐Negrini, Guilherme , Bellaver, Bruna , Lussier, Firoza Zubeida , Ferreira, Pâmela C.L. , Zatt, Bruno , Klunk, William E. , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.094383 Get It

AbstractBackgroundThe HEAD study aims to collect a large dataset of multiple tau‐PET tracers to provide robust anchor values for tau‐PET harmonization. Here, we tested the hypothesis that anchoring two tau tracer uptake values using head‐to‐head measurements has the potential to generate an accurate universal tau‐PET scale, named Uniτ(tau).MethodsWe assessed 200 individuals across the aging and AD spectrum (Training:HEAD data freeze 2.0, n=185; Testing:UPitt dataset (Gogola et al.), n=15) with [18F]Flortaucipir and [18F]MK‐6240 tau‐PET. SUVRs were processed to a common 8mm FWHM, with inferior cerebellar gray matter as the reference region (Pascoal et al.). Uniτ explored two anchoring/harmonization methods. First, we examined within‐tracer anchoring by creating anchor values based on the mean SUVR of Youngs (<25 years) and 95th percentile voxels from cognitively impaired individuals. Second, we explored within‐ plus between‐tracer anchoring, employing linear (e.g., piecewise) and non‐linear regressions. To address the inherent problem of discontinuity of piecewise transformations, we implemented two smoothing methods at the inflection point between equations, transforming them into a continuous function.ResultsUniτ scale anchoring within‐tracer resulted in similar estimates for high values, but less accurate in the lower range (Figure 1,2). Anchoring within‐ plus between‐tracer improved estimate consistency, with the piecewise transformation generating the best results. The piecewise smoothing equation yielded estimates comparable to those obtained from the piecewise method without smoothing. This allowed for the use of a single formula. In addition, this leads to more robust results when the goal is to study longitudinal changes in the scale (data not shown). UPitt testing dataset showed similar results to the training set (Figure 3).ConclusionOur preliminary findings suggest that anchoring tau‐PET values both within and between tracers has the potential to harmonize tau‐PET tracers, while preserving their characteristics. Currently, piecewise smoothing is the preferred method for Uniτ, but we are continuously fine‐tuning scale parameters as we acquire more data. The final scale parameters will be determined based on extensive training and testing data from multiple tracers. This cautious methodology holds the promise of delivering reliable, robust, and reproducible results, ensuring safe usage of the scale in clinical trials, and potentially paving the way for future use in clinical practice.
Biological Factors Influencing [18F]MK6240 and [18F]FTP Correlation in Target Regions
Tsai, Hsin‐Yeh, Tudorascu, Dana , Rahmouni, Nesrine , Servaes, Stijn , Stevenson, Jenna , Ziontz, Jacob , Lowe, Val J. , Soleimani‐Meigooni, David N. , Oh, Hwamee , Jagust, William J., Baker, Suzanne L. , Tissot, Cécile , Tsai, Hsin‐Yeh, Therriault, Joseph , Lussier, Firoza Zubeida , Pezzoli, Stefania , Gordon, Brian A. , Pascual, Belén , Klunk, William E. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.094377 Get It

AbstractBackgroundThe association between [18F]Flortaucipir (FTP) and [18F]MK6240, two commonly used tau‐PET tracers in Alzheimer’s disease (AD), varies due to distinct binding properties and off‐target signal regions. Our study aims to elucidate the biological factors influencing this association and evaluate the applicability of a common equation across different on‐target regions.Method113 individuals from the HEAD dataset (11 young, 58 cognitively unimpaired elderly, and 44 cognitively impaired) underwent [18F]MK6240, [18F]FTP and Aß‐PET scans. Images were processed using the inferior cerebellar grey (CG) as the reference region, with subjects categorized by Aß status. Stepwise linear fitting identified off‐target (OFF) regions impacting tracer associations within the whole cortex, Braak and temporal‐meta regions of interest (ROIs). OFF regions included were a composite mask (pallidum, putamen, caudate ‐ PPC) to address collinearity in subcortical nuclei, as well as the region with the greatest partial volume effects (PVE) on the ROI (meninges, choroid plexus, and the hotspot medial to entorhinal cortices (EC)). Akaike information criteria (AIC) analyses tested linear models with various off‐target regions.ResultPPC and PVE regions influenced tracer association in on‐target regions. PPC binding is associated with age. PPC and meninges retention, along with Aß status interaction, demonstrated the best model fit for the whole cortex (Figure 1). Weighting factors derived from the whole cortex model were applied to Braak regions and temporal meta‐ROI. Braak III‐VI and temporal‐meta ROI showed optimal models including OFF regions and Aß status interaction (Figure 2). Forcing the whole equation gave optimal results. For Braak I (EC), adding the OFF covariates only was the best model. For Braak II (hippocampus), the best model included OFF regions and the interaction with Aß status (Figure 2). Forcing the whole cortex equation onto Braak I and Braak II yielded suboptimal fits.ConclusionHarmonizing tau‐PET tracers involves considering significant covariates. Integrating meningeal and age‐related off‐target regions enhances [18F]MK6240 and [18F]FTP association in on‐target regions, further improved by Aß status inclusion. While the whole cortex model may not suit early ROI, it proves effective for Braak III and beyond. Creating an equation for tracer translation necessitates incorporating meningeal and subnuclei off‐target retention.
Creating Universal Tau PET Scale (Uniτ) Parametric Images – The HEAD Study
Amaral, Lívia , Finn, Quentin, Tudorascu, Dana , Jagust, William J. , Lowe, Val J. , Soleimani‐Meigooni, David N. , Oh, Hwamee , Baker, Suzanne L. , Povala, Guilherme , Bauer‐Negrini, Guilherme , Bellaver, Bruna , Lussier, Firoza Zubeida , Ferreira, Pâmela C.L. , Zatt, Bruno , Klunk, William E. , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.094123 Get It

AbstractBackgroundThe HEAD study focuses on collecting an extensive dataset from various tau‐PET tracers, aiming to establish robust anchor values, which are essential for harmonizing tau‐PET measurements. Here, we aim to showcase the capability of converting 3D tau‐PET images into a common scale using the Universal Tau‐PET Scale, Uniτ (tau), and to use these 3D images to subsequently obtain ROIs as needed.MethodsWe assessed 185 individuals across the aging and AD spectrum from the HEAD study, with [18F]Flortaucipir and [18F]MK‐6240 tau‐PET tracers. Tau‐PET SUVR images were standardized to a common 8mm FWHM, using the inferior cerebellar gray matter as the reference region. We generated Uniτ Tau‐PET 3D images using a single formula based on Meta‐temporal parameters in two steps: first, within‐tracer anchoring based on young (<25 years) and cognitively impaired individuals; second, between‐tracer anchoring using a piecewise transformation from [18F]Flortaucipir to [18F]MK‐6240, with smoothing at the piecewise inflection point. Subsequently, we extracted mean Uniτ values from these 3D images for key ROIs, including meta‐temporal, mesial, temporo‐parietal, frontal, and Braak stages III‐VI. Finally, we correlated Uniτ values across ROIs between the two tracers to evaluate the accuracy of estimates from the voxel‐wise transformation.ResultsThe original SUVR images present large differences between the two tau‐PET tracers (Figure 1). However, upon applying the Uniτ piecewise transformation with smoothing to all brain voxels, we were able to reasonably harmonize these images to the Uniτ scale, substantially reducing visual variability. Notably, the mean Uniτ values for the ROIs extracted from these harmonized 3D tau‐PET brain images demonstrated a high level of association between the two tracers (Figure 2). Furthermore, estimates generated from ROIs or extracted from our 3D parametric Uniτ model yielded identical estimates (Figure 3).ConclusionThe strong associations between tracers after directly harmonizing 3D images to Uniτ scale using the piecewise transformation with smoothing, underscore the effectiveness of the proposed method. This approach provides a reliable and standardized way to compare tau‐PET data across different tracers. Our results indicate the feasibility of harmonizing 3D tau‐PET images without relying on pre‐established ROIs, overcoming the limitation of restricting the analysis to only few brain regions.